Akeso Reports Ivonescimab OS Benefit in HARMONi-2
Hong Kong, September 3, 2026 Akeso, Inc. has announced that a prespecified interim analysis of overall survival (OS) in...
Pembrolizumab
Advertisement
AIM ImmunoTech Wins U.S. Patent for Ampligen Cancer Therapy
OCALA, Fla., August 31, 2026 AIM ImmunoTech Inc. announced that the U.S. Patent and Trademark Office (USPTO) has granted...
Merck and Moderna Report Phase 3 Melanoma Success
Rahway, New Jersey, and Cambridge, Massachusetts, August 19, 2026 Merck and Moderna announced positive topline results from the Phase...
AstraZeneca Discontinues eVOLVE-Lung02 Phase 3 Trial
Cambridge, UK — August 17, 2026 AstraZeneca announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig...
Phanes Therapeutics Gains FDA Fast Track for Spevatamig
San Diego, California, August 14, 2026 Phanes Therapeutics, Inc., a clinical-stage biotechnology company focused on immuno-oncology drug discovery and...
Advertisements
Eikon Therapeutics Selects EIK1001 Dose for Phase 2/3 Melanoma Trial
MILLBRAE, Calif., August 11, 2026 Eikon Therapeutics announced the selection of a 0.60 mg/m² dose of EIK1001 for patients...
BioInvent Receives FDA Fast Track Designation for BI-1808
LUND, Sweden, August 7, 2026 BioInvent International AB announced that the U.S. Food and Drug Administration (FDA) has granted...
Obsidian Therapeutics Enrolls First Patient in Registration-Enabling Agni-01 Melanoma Trial
CAMBRIDGE, Mass., August 5, 2026 Obsidian Therapeutics announced the enrollment of the first patient in the registration-enabling cohort of...
Summit Therapeutics Launches Global Phase 3 Ivonescimab Trial in Bladder Cancer
MIAMI, August 5, 2026 Summit Therapeutics announced the launch of the Phase II/III HARMONi-GU1 study, the company’s first global...
Immutep Announces ESMO 2026 Presentation for EFTISARC-NEO Trial
SYDNEY, Australia – July 24, 2026 Immutep Limited has announced that an abstract from its investigator-initiated Phase II EFTISARC-NEO...
Advertisement
